METTL16 promotes taxane resistance in Triple-Negative Breast Cancer through m6A-dependent translational upregulation of ABCB1

This study identifies METTL16 as a critical driver of taxane resistance in triple-negative breast cancer that promotes ABCB1 translation via m6A modification, establishing METTL16 as a cancer-selective therapeutic target to restore drug sensitivity.

The Gist

The Big Picture: The "Unbreakable" Cancer

Imagine Triple-Negative Breast Cancer (TNBC) as a very aggressive, shape-shifting criminal. Doctors try to catch it using a powerful net called Taxane chemotherapy (drugs like Taxol). This net works by freezing the cell's internal scaffolding, stopping the cancer from dividing and killing it.

But often, the cancer learns to dodge the net. It becomes "resistant," meaning the drugs stop working, and the tumor grows back. This paper discovers how the cancer learns to dodge the net and, more importantly, how to break its escape route.

The Villain: METTL16 (The "Translator" Gone Rogue)

The researchers found a specific protein called METTL16. Think of METTL16 as a translator or a foreman inside the cancer cell's factory.

Normally, cells have instructions (mRNA) written in a complex code. METTL16's job is to read these instructions and add a special "highlight" (called m6A) to them. Usually, this highlight tells the factory's workers (ribosomes) to work faster and harder on specific projects.

In healthy cells, this is fine. But in this resistant cancer, METTL16 goes rogue. It starts highlighting a very dangerous instruction manual: the one for a protein called ABCB1.

The Escape Artist: ABCB1 (The "Trash Can")

ABCB1 is a protein that acts like a high-powered trash can or a bouncer on the cell's door. Its job is to grab toxic drugs (like Taxol) and throw them out of the cell before they can do any damage.

• The Problem: In resistant cancer cells, there is too much ABCB1. The cancer cell is constantly throwing the chemotherapy drugs out the door, so the drugs never get a chance to kill the cancer.
• The Discovery: The researchers found that METTL16 is the reason there is so much ABCB1. It doesn't just tell the cell to make more ABCB1 instructions; it tells the cell to translate those instructions into actual trash cans much faster. It's like a foreman shouting, "Build trash cans! Build them fast! Ignore the other work!"

The Mechanism: How They Proved It

The team did a series of experiments to prove this connection:

1. The "Highlight" Check: They showed that METTL16 physically grabs the ABCB1 instructions and puts the "m6A highlight" on them.
2. The Factory Floor: They looked at the "assembly line" (ribosomes). When METTL16 was present, the assembly lines were packed with workers building ABCB1 trash cans. When they removed METTL16, the workers stopped, and the trash cans disappeared.
3. The Drug Test: When they blocked METTL16, the cancer cells stopped throwing out the Taxol. The drug stayed inside, the cell's scaffolding froze, and the cancer died.

The "Achilles' Heel": Why This is a Big Deal

Here is the most exciting part of the paper. The researchers found that METTL16 isn't just helping the cancer resist drugs; the cancer actually needs METTL16 to stay alive.

• The Analogy: Imagine the cancer cell is a house built on a shaky foundation. METTL16 is the only thing holding the roof up.
  • In the Cancer: If you remove METTL16, the roof collapses, and the cancer cell dies immediately.
  • In Normal Cells: If you remove METTL16 from a healthy breast cell, the house gets a little wobbly, but it doesn't collapse. The healthy cell survives.

This means METTL16 is a cancer-selective target. You can attack it to kill the cancer without hurting the healthy people around it.

The Solution: The "Anti-Translator"

The researchers tested a new type of medicine called a Vivo-Morpholino. Think of this as a sticky note that you put over the foreman's mouth (METTL16).

• In the Lab: When they stuck this note on the cancer cells, the foreman stopped shouting. The cancer stopped making trash cans, the Taxol stayed inside, and the cancer died.
• In Mice: They injected this "sticky note" into mice with tumors. The tumors shrank significantly.

The Takeaway

This paper solves a mystery: Why does Taxol stop working?
Answer: Because a rogue foreman (METTL16) is speeding up the production of drug-ejecting trash cans (ABCB1).

The Good News: We found a way to silence that foreman. By using a "sticky note" drug (Morpholino) to stop METTL16, we can:

1. Stop the cancer from throwing out the drugs.
2. Kill the cancer cell directly because it can't survive without METTL16.
3. Do this without hurting healthy cells.

This opens the door for new treatments that could help patients who have stopped responding to standard chemotherapy.

Technical Summary

1. Problem Statement

Triple-Negative Breast Cancer (TNBC) is an aggressive subtype lacking estrogen, progesterone, and HER2 receptors, making taxane-based chemotherapy (e.g., paclitaxel, docetaxel) the primary treatment. However, the rapid emergence of chemoresistance leads to recurrence and poor clinical outcomes. A major mechanism of taxane resistance is the overexpression of the multidrug transporter ABCB1 (P-glycoprotein), which actively effluxes drugs from cells. While ABCB1 upregulation is well-known, the upstream epigenetic and epitranscriptomic drivers regulating its expression in TNBC remain poorly understood. There is an urgent need to identify novel therapeutic targets that can reverse resistance without the high toxicity associated with direct ABCB1 inhibitors.

2. Methodology

The study employed a multi-faceted approach combining unbiased genetic screening, molecular biology, biochemical assays, and in vivo models:

• Unbiased Genetic Screening: Used Validation-Based Insertional Mutagenesis (VBIM) with lentiviral vectors to identify genes whose overexpression confers taxane resistance in MDA-MB-468 cells.
• Cell Models: Utilized multiple TNBC cell lines (MDA-MB-231, MDA-MB-468, SUM159PT, HCC70) and their acquired paclitaxel-resistant (PacR) derivatives. Non-malignant hTERT-HME1 cells served as controls.
• Genetic Manipulation:
  • Overexpression: Lentiviral transduction of Wild-Type (WT) METTL16 and a catalytically inactive mutant (N184A).
  • Knockdown/Knockout: shRNA-mediated knockdown and CRISPR-Cas9-mediated knockout of METTL16.
  • Pharmacological Inhibition: Use of Vivo-Morpholinos (antisense oligonucleotides) to block METTL16 translation.
• Molecular & Biochemical Assays:
  • RNA-Protein Interactions: RNA Immunoprecipitation (RIP) to confirm METTL16 binding to ABCB1 mRNA.
  • m6A Modification: MeRIP-qPCR to quantify N6-methyladenosine (m6A) levels on ABCB1 transcripts.
  • Translation Efficiency: Polysome profiling to assess ribosome loading and translation rates of ABCB1 mRNA.
  • Drug Accumulation: Flow cytometry using fluorescent paclitaxel (Flutax-2) and Calcein-AM efflux assays to measure intracellular drug retention.
  • Apoptosis: Annexin V/PI staining to assess cell death mechanisms.
• In Vivo Studies: Orthotopic xenograft models in NSG mice treated with METTL16-targeting Morpholinos.
• Clinical Correlation: Bioinformatics analysis of public TNBC datasets (e.g., Breast cancer-GenExMiner) to correlate METTL16 and ABCB1 expression with patient survival and molecular subtypes.

3. Key Contributions

• Discovery of METTL16 as a Resistance Driver: Identified the RNA methyltransferase METTL16 as a novel, previously unrecognized epi-transcriptomic driver of taxane resistance in TNBC.
• Mechanistic Elucidation: Defined a specific METTL16-ABCB1 axis. The study demonstrates that METTL16 does not increase ABCB1 mRNA abundance but rather enhances its translation via m6A methylation.
• Catalytic Dependency: Proved that the methyltransferase activity of METTL16 (specifically the N184 residue) is essential for conferring resistance; catalytic inactivation abolishes the resistance phenotype.
• Therapeutic Vulnerability: Established that TNBC cells exhibit a cancer-selective dependency on METTL16 for survival, whereas non-malignant mammary epithelial cells are less affected, suggesting a therapeutic window.
• Translational Strategy: Validated Vivo-Morpholinos as a viable therapeutic strategy to inhibit METTL16 translation and reverse resistance in vivo.

4. Key Results

• METTL16 Drives Resistance:
  • Unbiased screening identified METTL16 as a top hit for docetaxel resistance.
  • Overexpression of METTL16 in sensitive TNBC cells conferred resistance to both docetaxel and paclitaxel.
  • Conversely, METTL16 was elevated in acquired PacR cell lines, and its depletion restored taxane sensitivity.
• Regulation of ABCB1:
  • METTL16 overexpression increased ABCB1 protein levels without altering ABCB1 mRNA levels, indicating post-transcriptional regulation.
  • METTL16 depletion reduced ABCB1 protein and increased intracellular paclitaxel accumulation (measured by Flutax-2 retention).
• m6A-Dependent Translational Control:
  • Binding: RIP assays confirmed METTL16 directly binds ABCB1 mRNA.
  • Methylation: MeRIP-qPCR showed METTL16 catalyzes m6A modification at specific sites (A2368, A4141, A4497) on ABCB1 mRNA, located within predicted hairpin structures.
  • Translation: Polysome profiling revealed that METTL16 shifts ABCB1 mRNA from monosomes to polysomes (increasing the P:M ratio), indicating enhanced ribosome loading and translation. This effect was lost in cells expressing the catalytically inactive N184A mutant.
• Clinical Relevance:
  • High METTL16 expression correlated with shorter relapse-free survival (RFS) in chemotherapy-treated TNBC patients.
  • A significant positive correlation exists between METTL16 and ABCB1 expression, particularly in the aggressive Mesenchymal-like Immune-Altered (MLIA) TNBC subtype.
• Therapeutic Efficacy & Selectivity:
  • In Vitro: METTL16-targeting Morpholinos reduced METTL16 protein, decreased ABCB1 levels, and significantly reduced survival of PacR cells.
  • In Vivo: Morpholino treatment significantly suppressed tumor growth in PacR xenografts.
  • Selectivity: CRISPR-mediated knockout of METTL16 caused profound cell death in TNBC lines (70-80% reduction) but only modest effects (30% reduction) on normal mammary epithelial cells, highlighting a cancer-selective dependency.

5. Significance

This study fundamentally shifts the understanding of taxane resistance from a purely transporter-centric view to an epitranscriptomic regulatory model. By identifying METTL16 as the upstream regulator that "switches on" ABCB1 translation via m6A methylation, the authors provide a new mechanistic target for overcoming multidrug resistance.

The findings are significant because:

1. Novel Mechanism: It links m6A modification directly to the translational upregulation of a major drug efflux pump.
2. Therapeutic Target: It identifies METTL16 as a "druggable" vulnerability. Unlike direct ABCB1 inhibitors (which have failed clinically due to toxicity and redundancy), targeting METTL16 simultaneously disrupts drug efflux and impairs the survival of TNBC cells.
3. Precision Medicine: The strong correlation with the MLIA subtype suggests this approach could be particularly effective for the most aggressive and therapy-refractory TNBC patients.
4. Translational Potential: The successful use of Vivo-Morpholinos in xenograft models demonstrates a feasible path toward clinical application for reversing chemoresistance.